Jonathan D. Tward, MD, Ph.D. from the Huntsman Cancer Institute and U Health – University of Utah speaks about New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics"™ Prolaris® test to Guide Treatment for Prostate Cancer.
Link to Press Release –
https://myriad.com/investors/news-release/news-release-detail/?newsItemId=21816
SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) " Myriad Genetics, Inc. (NASDAQ: MYGN), a pioneer in genetic testing and precise medicine, today revealed additional evidence further validating the prognostic strength of its Prolaris® test and its ability to reliably predict which men with more advanced prostate cancer will benefit from therapy intensification and which patients can safely treat Jonathan Tward, M.D., Ph.D., associate professor in the Department of Radiation Oncology at the University of Utah, presented this second validation analysis during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU).
248,530 new cases of prostate cancer are predicted to be diagnosed this year in the U.S., according to predictions by the American Cancer Society. Although early screening tests have helped reduce the mortality rate, they may also contribute to clinically irrelevant overdiagnosis and overtreatment of a disease. The Prolaris test will more reliably assess the aggressiveness of cancer allowing for more targeted care and avoidance of more severe treatments with a patient’s parallel morbidities.
The new data comes from a second study following previous data, recently published in January 2021 in Clinical Genitourinary Cancer, which included surgically or radiation-treated men. This new research merged a molecular risk score threshold for Prolaris with a clinical model for predicting the value of androgen deprivation therapy for a patient. Prolaris has determined that approximately one in two men with an adverse intermediate-risk and one in five men with high-risk prostate cancer are below the proposed threshold for aggressive disease and can thus be handled safely with less intensive therapy while retaining the benefits of treatment. Additional primary results showed that the Prolaris test was a precise predictor of metastatic disease progression.
In March 2020, to provide biomarker testing for unfavorable intermediate and high-risk prostate cancer patients, the National Comprehensive Cancer Network revised its clinical guidelines. With the revised criteria, for these extended signs, Prolaris was one of only two prognostic measures to be considered. Approximately 60% of men with prostate cancer currently have insurance or Medicare coverage to Prolaris, and Countless continues to work towards improving access such that the full advantages of the test can be used for any person facing difficult treatment decisions.